CAMBRIDGE, Mass., Oct. 13, 2021 /PRNewswire/ -- Invaio
Sciences, Inc., a Flagship Pioneering company unlocking the
potential of natural systems to accelerate the transition to
sustainable agriculture to urgently address climate change, has
entered into a $50 million loan and
security agreement with K2 HealthVentures (K2HV), a healthcare and
life sciences-focused investment firm.
The funds will be used to accelerate the research, development
and commercialization of Invaio's platforms which are focused on
discovering natural active ingredients, developing unique precision
delivery systems, and understanding novel modes of action. Invaio's
pioneering solutions have the potential to reduce the use of
chemical pesticides and fertilizers, conserve more water, and
improve the efficiency of the agricultural food system for the
benefit of consumers and the planet.
"Invaio's partnership with K2HV will help us expand our
geographic footprint and accelerate the development of breakthrough
platforms focused on developing integrated solutions in three
market segments: perennials, row crops and vegetable crops," said
Ignacio Martinez, co-founder and CEO
of Invaio and General Partner at Flagship Pioneering. "Our ambition
is to build the most impactful and valuable crop health company on
the planet. The world is changing quickly, and food production
practices must adapt to keep pace with evolving consumer demands,
changing environmental conditions, and increased stress on
ecological resources."
"Thankfully, over the last two decades, human disease management
has increasingly utilized safer and more effective precision
medicine techniques. The agricultural world has not shifted to this
paradigm and still suffers from ineffective pest and disease
management and harmful consequences to the environment. We believe
Invaio's suite of platform technologies is the precision medicine
answer for the agriculture world," said Parag Shah, founding
managing director and CEO of K2 HealthVentures. "This financing
follows our strategy of partnering with pioneering life science
technology companies with world class management that aim to
deliver solutions for critical global challenges."
About Invaio
Invaio Sciences, Inc., a Flagship Pioneering company focused on
unlocking the potential of natural systems to accelerate the
transition to sustainable agriculture to urgently address climate
change challenges. Founded by Flagship Pioneering in 2018, Invaio
leverages discoveries from diverse fields including human
therapeutics, agriculture, environmental science, and advanced
manufacturing. For more information, please visit
www.invaio.com or follow us on Twitter or LinkedIn.
About Flagship Pioneering:
Flagship Pioneering conceives, creates, resources, and develops
first-in-category bioplatform companies to transform human health
and sustainability. Since its launch in 2000, the firm has, through
its Flagship Labs unit, applied its unique hypothesis-driven
innovation process to originate and foster more than 100 scientific
ventures, resulting in over $212 billion in aggregate
value. To date, Flagship has deployed over $2.5
billion in capital toward the founding and growth of its
pioneering companies alongside more than $19 billion of
follow-on investments from other institutions. The current Flagship
ecosystem comprises 42 transformative companies, including Axcella
Health (NASDAQ: AXLA), Codiak BioSciences (NASDAQ: CDAK)
Denali Therapeutics (NASDAQ: DNLI), Evelo Biosciences
(NASDAQ: EVLO), Foghorn Therapeutics
(NASDAQ: FHTX), Indigo Ag, Kaleido Biosciences
(NASDAQ: KLDO), Moderna (NASDAQ: MRNA), Rubius
Therapeutics (NASDAQ: RUBY), Sana Biotechnology
(NASDAQ: SANA), Seres Therapeutics (NASDAQ: MCRB), and
Sigilon Therapeutics (NASDAQ: SGTX).
About K2 HealthVentures
K2 HealthVentures is an
alternative investment firm focused on providing flexible,
long-term financing solutions to innovative private and public
companies in the life sciences and healthcare industries. The
investment team comprises collaborative, experienced professionals
with diverse backgrounds in finance and operations, as well as deep
domain knowledge across various healthcare sectors. A uniquely
flexible, permanent capital structure enables the firm to provide
creative, adaptive financing solutions and meet the evolving
capital needs of its portfolio companies as they grow. K2HV is
driven by dual goals of Profit and Purpose — aiming to fuel the
growth of innovative companies that will ultimately improve the
lives of patients and giving a percentage of investment profits
back to underserved areas in healthcare. www.k2hv.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/invaio-sciences-secures-50-million-debt-financing-to-develop-and-commercialize-agricultural-solutions-to-address-climate-change-301399396.html
SOURCE Invaio Sciences